Pairing PET with CT achieved better diagnostic accuracy than temporal artery biopsy (TAB) in patients with newly suspected giant cell arteritis (GCA), according to research presented recently at the 2018 American College of Rheumatology (ACR)/ Association of Reproductive Health Professional (AHRP) meeting in Chicago.
The technique is able to map the structure of small organic molecules, such as pharmaceuticals and hormones, with electron diffraction imaging—commonly used to chart larger proteins, according to a report published Oct. 19 by Science Magazine.
Utilizing non-displaceable binding potential (BPND) quantification with 18F-Flutemetamol PET imaging can better assess amyloid pathology in elderly patients with low amyloid buildup compared to traditional standard uptake value ratio (SUVr), reported authors of an Oct. 12 study in the Journal of Nuclear Medicine.
PET imaging could serve as an accurate, noninvasive substitute to liver biopsies in patients with chronic liver diseases, as detailed in research published in the October issue of The Journal of Nuclear Medicine.
Researchers from the Medical University of South Carolina (MUSC) Hollings Cancer Center in Charleston have received a three-year, $1.2 million grant from the U.S. Department of Defense to use molecular imaging tools to test antibody therapies for breast cancer—potentially producing fewer side effects.
NorthStar Medical Radioisotopes in Beloit, Wis. and the Janesville, Wis.-planned SHINE Medical Technologies may receive a portion of the $20 million in federal technology funding bill approved by President Donald Trump to produce molybdenum-99 (Mo-99).
A new hybrid nanoplatform that simultaneously uses three types of imaging modalities—MRI, CT and fluorescence optical imaging—to locate tumors could give a new edge to molecular imaging and tumor diagnosis.
The World Molecular Imaging Society (WMIS) has awarded Robert Gillies, PhD, the 2018 Gold Medal Award to honor his lifetime of research in cancer molecular imaging and cancer biology, according to a WMIS press release.
Alzheimer’s could be diagnosed earlier if the blood-brain barrier was monitored as a biomarker and potential drug target using MRI or PET, according to research published online Sept. 24 in Nature Neuroscience.
BlueCross BlueShield of Tennessee announced it will expand Medicare coverage for cardiac PET, according to the Society for Nuclear Medicine and Molecular Imaging (SNMMI). The change will take effect later this year.
In patients with diagnosed Alzheimer’s disease (AD), [18F] flortaucipir PET imaging proved accurate in distinguishing AD from other neurodegenerative diseases, according to a multicenter study published in JAMA.
Amyloid load (AβL) imaged in vivo using [18F]Florbetapir PET is a more sensitive biomarker for measuring the global amyloid (Aβ) burden compared to composite standardized uptake value ratio (SUVr), reported authors of a Sept. 6 Journal of Nuclear Medicine study.